PPT-Telaprevir

Author : karlyn-bohler | Published Date : 2018-01-11

BID versus q8 in Treatment Naïve GT1 OPTIMIZE Study C211 Phase 3 Treatment Naïve Buti M et al Gastroenterology 2013 Dec 4 Epub ahead of print Source Buti

Presentation Embed Code

Download Presentation

Download Presentation The PPT/PDF document "Telaprevir" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Telaprevir: Transcript

BID versus q8 in Treatment Naïve GT1 OPTIMIZE Study C211 Phase 3 Treatment Naïve Buti M et al Gastroenterology 2013 Dec 4 Epub ahead of print Source Buti M et al Gastroenterology 2013 Dec 4 . Department of Medicine. University of Toronto. Complicated cases. CASE 1 . 54 . yr. /o. man . HIV positive 8 . yrs. ago. Tenofovir. /FTC/RTV/. Atazanavir. . x 4 . yrs. Previously documented NNRTI resistance with Y181C, G190A,and mixed m184v/. Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. Chapter 2. – Important Hepatitis C Protease Inhibitor Drug Interactions in Mono and HIV . Morris Sherman MD . BCh. PhD FRCP(C) . Associate Professor of Medicine. University of Toronto. Protease Inhibitors . in Chronic . Hepatitis C:. An . Update. COMPLETE SLIDE DECK (Chapters 1 – 6). November 2012. Todd S. Wills, MD. SPNS HCV Treatment Expansion Initiative. Evaluation and Technical Assistance Center. Infectious Disease Specialist. HCV Response Rates in HIV+ and HIV- Patients Treated With . PegIFN. JournalofHepatologyvol.56 Keywords:HCV;HepattitisC;Skin;Dermatology;Telaprevir;Direct-actinganti-virals;Proteaseinhibitor.Received23June2011;receivedinrevisedform26July2011;accepted2August2011 Cutaneo Naïve GT-1. ADVANCE (Study 108). Phase . 3. Treatment. . Naïve. Jacobson IM, et. al. N . Engl. J Med. 2011;364:2405-16. .. Source: Jacobson . IM, et. al. . N . Engl. J Med. 2011;364:2405-16.. Telaprevir for Treatment-Naïve HCV Genotype . versus . Telaprevir. . with PR in GT1 . ATTAIN Trial. Phase . 3. Treatment. . Experienced. Reddy KR. , . et al. . Lancet Infect Dis. 2015;15:27-35.. Source: Reddy KR. , et al. Lancet Infect Dis. 2015;15:27-35.. Naïve GT-1. ILLUMINATE (Study 111). Phase . 3. Treatment. . Naïve. Sherman KE, et. al. N . Engl. J Med. 2011;365:1014-24.. Source: Sherman . KE, et. al. . N . Engl. J Med. 2011;365:1014-24.. Telaprevir for Treatment-Naïve HCV Genotype . Regina . Ubaldi. -Rosen, CRNP. ELLAH NOTA, CRNP. GUIDANCE FOR HCV/HIV Co-infection Programs. AIDS CARE GROUP. Is a . non-profit organization that provides medical care, dental care, and social services to uninsured and underinsured minority residents of Chester, Delaware County, . Gene LeSage, MD, FACP, AGAF. Objectives. HCV epidemiology, risk factors, diagnosis and prognosis. Interferon (IFN) and Ribavirin (RBV) based therapy. Direct acting anti-viral . (. DAA) therapies. HCV Epidemiology. Gene LeSage, MD, FACP, AGAF. Objectives. HCV epidemiology, risk factors, diagnosis and prognosis. Interferon (IFN) and Ribavirin (RBV) based therapy. Direct acting anti-viral . (. DAA) therapies. HCV Epidemiology. Créteil, France. Paris, 30 January 2012. Triple therapy today:. Safety management in clinical practice. Telaprevir. placebo-controlled Phase II/III studies: . summary of AEs during . telaprevir. /placebo phase. Mark Sulkowski, . MD. Professor of Medicine. Medical Director, Viral Hepatitis Center . Johns Hopkins University. Baltimore Maryland USA. Liver disease is the second leading specific causes of death amongst HIV-positive individuals in the D:A:D study. really necessary?. Peter . Ferenci. Medical University of Vienna. Treatment . of. . chronic. non-. A,non. -B . hepatitis. . with. . recombinant. human . alpha. . interferon. . A . preliminary.

Download Document

Here is the link to download the presentation.
"Telaprevir"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.